This results in IDO inhibition, which regulates the TRP/KYN pathway and subsequently impacts monoamine neurotransmitter transmission and neuron morphology in brain tissue, thereby exerting a certain antidepressant effect
Conventional Treatments vs
Proposed pathways include modulation of multiple neurotransmitter systems (influencing serotonin, dopamine, norepinephrine, GABA, glutamate levels), possible involvement of NMDA receptors, alpha-1 adrenergic signaling (e.g., potentiating pineal acetyltransferase activity), inhibition of somatostatin release via dopaminergic routes, reduced ACTH/cortisol for stress buffering, and stimulated growth hormone or somatoliberin secretion
It is not an FDA approved medication, but it is made in pharmacies that are FDA approved and regulated